|
See related Maxipime powd for inj information |
|
|
|
Manufacturer |
Bristol-Myers Squibb |
|
Distributor |
DKSH |
|
Contents |
Cefepime HCl |
|
Indications |
Septicemia, meningitis, empiric treatment in febrile neutropenic patients. Lower resp tract infections, UTI (both complicated, including pyelonephritis & uncomplicated infections), skin & skin structure infections, intra-abdominal infections, gynecology infections. |
|
Dosage |
Adult & childn >12 yr Mild to moderate UTI 500 mg-1 g IM or IV 12 hrly. Mild to moderate infections other than UTI 1 g IM or IV 12 hrly. Severe infections 2 g IV 12 hrly. Very severe or life-threatening infections 2 g IV 8 hrly. Childn >2 mth-12 yr Pneumonia, UTI, skin & skin structure infection 50 mg/kg IV 12 hrly. Septicemia, meningitis, empiric treatment in febrile neutropenia 50 mg/kg IV 8 hrly. |
|
Contraindications |
Hypersensitivity to cephalosporins. |
|
Special Precautions |
Hypersensitivity to penicillins. Renal impairment. |
|
Adverse Drug Reactions |
Allergic skin reaction. Nausea, vomiting, diarrhoea, headache.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Maxipime powder for injection |
|
Maxipime 1 g x 1's |
|
Maxipime 2 g x 1's |
|
|
|
Manufacturer: |
Bristol-Myers Squibb |
|
Distributor: |
DKSH |
|
|
|
